We are live on ! Find out more
BIOT

Biotech Acquisition Company Class A Ordinary Shares
BIOT

Delisted

BIOT was delisted on the 2nd of February, 2023.

Back to rankings

28 hedge funds and large institutions have $70M invested in Biotech Acquisition Company Class A Ordinary Shares in 2021 Q1 according to their latest regulatory filings, with 28 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
28
Holders Change
+28
Holders Change %
–
% of All Funds
0.49%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
28
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CCP
Corbin Capital Partners
New York
+$8.99M
2
Citadel Advisors
Citadel Advisors
Florida
+$8.67M
3
MI
MMCAP International
Cayman Islands
+$5.81M
4
PAMP
Polar Asset Management Partners
Ontario, Canada
+$5.81M
5
ACM
Atalaya Capital Management
New York
+$5.39M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
CCP
1
Corbin Capital Partners
New York
$9.02M +$8.99M +928,124 New
Citadel Advisors
2
Citadel Advisors
Florida
$8.69M +$8.67M +895,433 New
MI
3
MMCAP International
Cayman Islands
$5.83M +$5.81M +600,000 New
PAMP
4
Polar Asset Management Partners
Ontario, Canada
$5.83M +$5.81M +600,000 New
ACM
5
Atalaya Capital Management
New York
$5.4M +$5.39M +556,875 New
Blackstone Inc
6
Blackstone Inc
New York
$4.86M +$4.84M +500,000 New
KCM
7
Kingstown Capital Management
New York
$2.92M +$2.91M +300,000 New
MP
8
Mangrove Partners
Connecticut
$2.92M +$2.91M +300,000 New
SC
9
Sculptor Capital
New York
$2.92M +$2.91M +300,000 New
FTCM
10
Fir Tree Capital Management
New York
$2.91M +$2.91M +300,000 New
TCM
11
Tenor Capital Management
New York
$2.73M +$2.72M +280,581 New
PC
12
Periscope Capital
Ontario, Canada
$2.39M +$2.38M +245,506 New
Hudson Bay Capital Management
13
Hudson Bay Capital Management
Connecticut
$1.94M +$1.94M +200,000 New
CH
14
CVI Holdings
Delaware
$1.94M +$1.94M +200,000 New
Bank of America
15
Bank of America
North Carolina
$1.38M +$1.37M +141,523 New
WA
16
Whitebox Advisors
Minnesota
$1.21M +$1.21M +125,000 New
Jane Street
17
Jane Street
New York
$1.03M +$1.02M +105,707 New
CP
18
Centerbridge Partners
New York
$972K +$968K +100,000 New
CCA
19
Castle Creek Arbitrage
Colorado
$971K +$968K +100,000 New
Marshall Wace
20
Marshall Wace
United Kingdom
$970K +$968K +99,986 New
Alyeska Investment Group
21
Alyeska Investment Group
Illinois
$875K +$872K +90,000 New
BCM
22
Basso Capital Management
Connecticut
$747K +$744K +76,850 New
Goldman Sachs
23
Goldman Sachs
New York
$584K +$582K +60,104 New
WRBC
24
W.R. Berkley Corp
Connecticut
$477K +$476K +49,124 New
KIM
25
Karpus Investment Management
New York
$243K +$242K +25,000 New
1
2

BIOT Hedge Fund Activity: Q1 2021 in Review

28 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Class A Ordinary Shares (BIOT) for Q1 2021, worth a combined $70M.

Buyers outnumbered sellers: 28 funds opened new BIOT positions and 0 closed out — a net gain of 28 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Corbin Capital Partners, opening a new position worth an estimated $8.99M.

  • 28 institutional investors held Biotech Acquisition Company Class A Ordinary Shares (BIOT) as of Q1 2021, up from 0 in Q4 2020.
  • Funds reported $70M of Biotech Acquisition Company Class A Ordinary Shares stock for Q1 2021.
  • 28 funds opened new Biotech Acquisition Company Class A Ordinary Shares positions in Q1 2021 and 0 closed out, a net change of +28 holders.
  • The largest Biotech Acquisition Company Class A Ordinary Shares buyer in Q1 2021 was Corbin Capital Partners, an estimated $8.99M added.

Based on aggregated 13F filings for Q1 2021.